Plain-English translation of NCT06993844 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This study is testing a new drug called ETX-636, which is designed to target cancer cells that have a specific genetic change called a PIK3CA mutation. The medication will be tested in three ways: by itself in people with various advanced cancers, and combined with another breast cancer drug in people with hormone receptor positive, HER2 negative breast cancer. The goal is to understand how safe this treatment is and how well it works.
Some cancers have a genetic mutation that makes them grow faster and become resistant to standard treatments. This medication was designed specifically to target cancers with this mutation, and researchers want to see if it can help patients whose cancers have stopped responding to other therapies.
You likely qualify if…
You likely don't qualify if…
After a 28-day screening period where your doctor will confirm you qualify, you will begin taking the medication either alone or in combination with fulvestrant (an existing breast cancer drug). Depending on which part of the study you are in, you will have regular clinic visits to check how you are tolerating the treatment, have blood tests and imaging scans to see if the cancer is responding, and report any side effects. The study will monitor both your safety and how your body processes the medication over time.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States